Scientists test new drug to supercharge Cancer-Fighting CAR-T cells
NCT ID NCT04855253
Summary
This early-stage trial is testing whether adding an experimental drug called E7777 before standard CAR-T cell therapy can improve results for adults with aggressive B-cell lymphomas that have returned or not responded to prior treatments. The drug aims to help the CAR-T cells work better by removing certain immune cells that might interfere with them. The study is currently suspended and was designed to find a safe dose and see if this approach helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.